庆大霉素/α半水硫酸钙载药体系的体外释药研究

对硫酸庆大霉素/α半水硫酸钙载药体系进行了模拟条件下体外释药研究，并对其晶体结构进行了分析。X-射线衍射分析结果表明，载药体系中一定含量的硫酸庆大霉素不会影响α半水硫酸钙的水化；模拟条件下体外释药研究表明，各种药物含量的载药体系均表现出了良好的缓释性能，持续释放时间超过了360h；随着试样中载药量的增加，其药物释放速率加快；另外，构制了均一分散和核壳结构两种载药体系，研究结果表明，均一分散型在前期释放速度要大于核壳结构型，而后期核壳结构型则比均一分散型要高。     

非均质基底表面团簇生长的周期性研究

根据基底表面客观存在杂相（不同材料、或同一材料的不同晶面等）的实验事实，考虑到粒子进出不同的相界具有不同的能耗，粒子在不同相基底上扩散具有不同的能耗，建立了非均质基底上扩散能量有限的多中心成核的DLA模型，对非均质基底上团簇的生长过程进行了Monte Carlo模拟。模拟结果表明：沉积在此类基底表面的粒子凝聚成具有分形结构的团簇的数目、团簇的回旋半径、团簇的分形维数均呈现一种周期性的变化。     

氮化铝薄膜改善LED散热性能的研究

研究了氮化铝薄膜对LED灯散热情况的影响，并与导热硅脂（Ks609）涂层的散热效果进行了比较，结果表明：导热涂层能加强LED的散热，氮化铝薄膜散热效果优于导热硅脂；对红、白、绿3种颜色LED，相同条件下，散热材料对红色LED的散热效果最好。研究结果为氮化铝薄膜应用于LED散热系统提供了参考数据。     

2-甲基-8-（9，9-二丁基芴）-3，5，7-三炔-2-辛醇的合成和性质研究

合成了一种新颖的乙炔衍生物，2-甲基-8-（9，9-二丁基芴）-3，5，7-三炔-2-辛醇（6a），并利用红外光谱（IR），紫外光谱（Uv），核磁（NMR），质谱（MS）等对其结构进行了表征。利用红外光谱（IR）和紫外光谱（Uv）对其拓扑固相聚合性质进行了研究。实验结果表明，这些化合物在加热和紫外光照射条件下都能够发生固相聚合，但得到的是结构复杂的聚合物。     

Estrogen receptor domains E and F: role in dimerization and interaction with coactivator RIP-140

We have used the yeast two-hybrid system to localize the ligand-dependent dimerization domain of the estrogen receptor-alpha (ER) to region E in vivo. In this system, the cDNAs corresponding to the A-D, E, E/F, A-E (deltaF), and full-length (wtER) domains of the human ER were each cloned into the yeast two-hybrid vectors GAL4 DB and GAL4 TA and expressed in different combinations in yeast harboring a GAL1-lacZ reporter. The reporter was used as a relative measure of the interaction between the ER domains, through reconstitution of GAL4 activity. We found that the interaction of E or E/F domains of the ER with full-length ER is estradiol dependent and estrogen responsive element independent, as measured by the reconstitution of GAL4 activity from GAL4-E domain-containing fusion protein interactions. In the presence of F domain, this activity is reduced 10-fold. The results suggest that sequences in the F domain are inhibitory to the dimerization signal that is present in the E region. We propose that the full-length ER contains intrinsic dimerization restraints contributed by regions outside domain E that are released upon binding hormone agonist. In addition, we have demonstrated that coactivator RIP140 is able to interact with the ER in vivo at the E domain of the receptor in the presence of estrogen. Yeast two-hybrid analysis shows that RIP140 does not homodimerize in the presence or absence of estrogens. We present evidence showing that the ER has the inherent ability to interact with RIP140 in the presence of antiestrogens, but sequences inherent in the ER itself that are present outside of the E domain compromise this ability.     

Billing third party payers for pharmaceutical care services

OBJECTIVE: To describe the steps pharmacists must complete when seeking compensation from third party payers for pharmaceutical care services. DATA SOURCES: Government publications; professional publications, including manuals and newsletters; authors' personal experience. DATA SYNTHESIS: Pharmacists in increasing numbers are meeting with success in getting reimbursed by third party payers for patient care activities. However, many pharmacists remain reluctant to seek compensation because they do not understand the steps involved. Preparatory steps include obtaining a provider/supplier number, procuring appropriate claim forms, developing data collection and documentation systems, establishing professional fees, creating a marketing plan, and developing an accounting system. To bill for specific patient care services, pharmacists need to collect the patient's insurance information, obtain a statement of medical necessity from the patient's physician, complete the appropriate claim form accurately, and submit the claim with supporting documentation to the insurer. Although many claims from pharmacists are rejected initially, pharmacists who work with third party payers to understand the reasons for denial of payment often receive compensation when claims are resubmitted. CONCLUSION: Pharmacists who follow these guidelines for billing third party payers for pharmaceutical care services should notice an increase in the number of paid claims.     

Organic sulfur compounds in petroleum of the Arkhangel’sko-Tanaiskoe field

The structural-group composition of sulfur compounds in concentrates isolated under mild conditions by two-step extraction with acetonitrile and sulfolane from crude oil of the Arkhangel’sko-Tanaiskoe field was studied. With the use of a combination of up-to-date chemical and instrumental techniques, the structures of 130 organic sulfur compounds were determined in the concentrates, of which 30 were first found in petroleum.